MétaCan
Menu
Back to cohort
Record W2111331724 · doi:10.1186/1741-7015-11-179

Personalizing health care: feasibility and future implications

2013· review· en· W2111331724 on OpenAlexaff
Brian Godman, Alexander Finlayson, Parneet Cheema, Eva Zebedin-Brandl, Iñaki Gutiérrez‐Ibarluzea, Jan Jones, Rickard E. Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogène, Alessandra Ferrario, Jurij Fürst, Kristina Garuolienè, Miguel Gomes, Katharine B. Harris, Alan Haycox, Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven‐Åke Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, D Tomek, Vera Vlahović–Palčevski, Luka Vončina, Magdalena Władysiuk, Menno van Woerkom, Durhane Wong‐Rieger, Corrine Zara, Raghib Ali, Lars L. Gustafsson

Bibliographic record

VenueBMC Medicine · 2013
Typereview
Languageen
FieldPharmacology, Toxicology and Pharmaceutics
TopicPharmacogenetics and Drug Metabolism
Canadian institutionsInstitute for Work & HealthSunnybrook Health Science CentreCentre for Global Health Research
FundersConservatoire National des Arts et MétiersVetenskapsrådetStockholms Läns LandstingKarolinska InstitutetNHS Health Scotland
KeywordsMedicinePharmacogenomicsPersonalized medicinePrecision medicineStakeholderHealth careRisk analysis (engineering)Variety (cybernetics)Intensive care medicinePharmacologyBioinformaticsPublic relationsPathology

Abstract

fetched live from OpenAlex

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.972
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.429
GPT teacher head0.565
Teacher spread0.136 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations102
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueBMC MedicineSame topicPharmacogenetics and Drug MetabolismFrench-language works237,207